SEL 399
Alternative Names: SEL-399Latest Information Update: 28 Mar 2024
At a glance
- Originator Asklepios BioPharmaceutical; Selecta Biosciences
- Developer Asklepios BioPharmaceutical; Cartesian Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Belgium (Parenteral)
- 02 Mar 2021 Preclinical pharmacodynamics data from a in unspecified indication released by Selecta Biosciences
- 17 Feb 2021 Phase-I clinical trials in Unspecified (In volunteers) in Belgium (Parenteral)